Contineum Therapeutics (CTNM) Free Cash Flow (2023 - 2026)

Contineum Therapeutics' Free Cash Flow history runs 4 years deep, the most recent figure standing at -$16.6 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 14.66% year-over-year to -$16.6 million in Q1 2026; TTM through Mar 2026 was -$57.7 million, a 46.95% decrease from a year earlier, with the FY2025 full-year figure at -$55.5 million, down 68.81% from the prior year.
• Free Cash Flow eased to -$16.6 million in Q1 2026 per CTNM's latest filing, from -$13.3 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $40.7 million in Q2 2023 and bottomed at -$16.6 million in Q1 2026.
• The 4-year median for Free Cash Flow is -$9.9 million (2024), against an average of -$6.6 million.
• Biggest YoY gain for Free Cash Flow was 10.0% in 2024; the steepest drop was 121.17% in 2024.
• Year by year, Free Cash Flow stood at -$11.0 million in 2023, then rose by 10.0% to -$9.9 million in 2024, then plunged by 33.85% to -$13.3 million in 2025, then fell by 24.96% to -$16.6 million in 2026.
• Per Business Quant, the three latest CTNM Free Cash Flow figures stand at -$16.6 million (Q1 2026), -$13.3 million (Q4 2025), and -$12.1 million (Q3 2025).